Log In
BCIQ
Print this Print this
 

MSX-122

  Manage Alerts
Collapse Summary General Information
Company Altiris Therapeutics Inc.
DescriptionCXC chemokine receptor 4 (CXCR4) inhibitor activated by stromal derived factor-1 (SDF-1)
Molecular Target CXC chemokine receptor 4 (CXCR4) (NPY3R)
Mechanism of ActionCXC chemokine receptor 4 (CXCR4) antagonist
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today